Not studied in pediatric patients
Has not been evaluated in pediatric patients aged <12 years or weighing <40 kg.
Is available through an FDA EUA for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg.
A clinical trial is currently evaluating the pharmacokinetics of<unk>  in children (ClinicalTrials.gov identifier NCT04431453).
Remdesivir
Ritonavir
Molnupiravir
Lopinavir
Foscarnet
Raltegravir
Baloxavir marboxil
Ribavirin